The changing landscape of acromegaly – an epidemiological perspective

Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10:804–26. https://doi.org/10.1016/S2213-8587(22)00244-3.

Article  CAS  PubMed  Google Scholar 

Dal J, Feldt-Rasmussen U, Andersen M, Kristensen L, Laurberg P, Pedersen L, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175:181–90. https://doi.org/10.1530/EJE-16-0117.

Article  CAS  PubMed  Google Scholar 

Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020;182:523–31. https://doi.org/10.1530/EJE-20-0019.

Article  CAS  PubMed  Google Scholar 

Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocr Relat Cancer. 2017;24:505–18. https://doi.org/10.1530/ERC-17-0253.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caron P, Brue T, Raverot G, Tabarin A, Cailleux A, Delemer B, et al. Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study. Endocrine. 2019;63:120–9. https://doi.org/10.1007/S12020-018-1764-4.

Article  CAS  PubMed  Google Scholar 

Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–73. https://doi.org/10.1038/S41431-019-0508-0.

Article  PubMed  Google Scholar 

Aagaard C, Christophersen AS, Finnerup S, Rosendal C, Gulisano HA, Ettrup KS, et al. The prevalence of acromegaly is higher than previously reported: Changes over a three-decade period. Clin Endocrinol (Oxf). 2022;97:773–82. https://doi.org/10.1111/CEN.14828.

Article  PubMed  Google Scholar 

Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017;176:645–55. https://doi.org/10.1530/EJE-16-1064.

Article  CAS  PubMed  Google Scholar 

Ohno H, Yoneoka Y, Jinguji S, Watanabe N, Okada M, Fujii Y. Has acromegaly been diagnosed earlier? J Clin Neurosci. 2018;48:138–42. https://doi.org/10.1016/J.JOCN.2017.10.086.

Article  PubMed  Google Scholar 

Dimaraki EV, Jaffe CA, Demott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002;87:3537–42. https://doi.org/10.1210/JCEM.87.8.8658.

Article  CAS  PubMed  Google Scholar 

Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–51. https://doi.org/10.1210/JC.2014-2700.

Article  CAS  PubMed  Google Scholar 

Dal J, Nielsen EH, Rasmussen UF, Andersen M, Feltoft CL, Vestergaard P, et al. Disease control and gender predict the socioeconomic effects of acromegaly: a nationwide cohort study. J Clin Endocrinol Metab. 2020;105:2975–82. https://doi.org/10.1210/CLINEM/DGAA405.

Article  Google Scholar 

Störmann S, Cuny T. The socioeconomic burden of acromegaly. Eur J Endocrinol. 2023;189. https://doi.org/10.1093/ejendo/lvad097.

Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179:59–71. https://doi.org/10.1530/EJE-18-0255.

Article  CAS  PubMed  Google Scholar 

Dal J, Leisner MZ, Hermansen K, Farkas DK, Bengtsen M, Kistorp C, et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J Clin Endocrinol Metab. 2018;103:2182–8. https://doi.org/10.1210/JC.2017-02457.

Article  PubMed  Google Scholar 

Maione L, Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33. https://doi.org/10.1016/J.BEEM.2019.02.001.

Burton T, Le Nestour E, Neary M, Ludlam WH. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016;19:262–7. https://doi.org/10.1007/s11102-015-0701-2.

Article  PubMed  PubMed Central  Google Scholar 

Broder MS, Chang E, Cherepanov D, Neary MP, Ludlam WH. Incidence and prevalence of acromegaly in the United States: a claims-based analysis. Endocr Pract. 2016;22:1327–35. https://doi.org/10.4158/EP161397.OR.

Article  PubMed  Google Scholar 

Caputo M, Ucciero A, Mele C, De Marchi L, Magnani C, Cena T, et al. Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region. Italy J Endocrinol Invest. 2019;42:397–402. https://doi.org/10.1007/S40618-018-0928-7.

Article  CAS  PubMed  Google Scholar 

Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G, et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021;185:251–63. https://doi.org/10.1530/EJE-21-0216.

Article  CAS  PubMed  Google Scholar 

Kerbel J, Cano-Zaragoza A, Espinosa-Dorado R, García De La Torre K-E, Mercado M. Real world data on the epidemiology, diagnosis, and treatment of acromegaly: a registries-based approach. Arch Med Res. 2023;54:102856. https://doi.org/10.1016/j.arcmed.2023.102856.

Article  PubMed  Google Scholar 

Placzek H, Xu Y, Mu Y, Begelman SM, Fisher M. Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J Manag Care Spec Pharm. 2015;21:1106–14. https://doi.org/10.18553/JMCP.2015.21.12.1106.

Article  PubMed  Google Scholar 

Yun SJ, Lee JK, Park SY, Chin SO. Descriptive epidemiology and survival analysis of acromegaly in Korea. J Korean Med Sci. 2021;36:1–10. https://doi.org/10.3346/JKMS.2021.36.E159.

Article  Google Scholar 

Park KH, Lee EJ, Seo GH, Ku CR. Risk for acromegaly-related comorbidities by sex in Korean acromegaly. J Clin Endocrinol Metab. 2020;105:1815–26. https://doi.org/10.1210/clinem/dgz317.

Article  Google Scholar 

Wu JC, Huang WC, Chang HK, Ko CC, Lirng JF, Chen YC. Natural history of acromegaly: incidences, re-operations, cancers, and mortality rates in a national cohort. Neuroendocrinology. 2020;110:977–87. https://doi.org/10.1159/000505332.

Article  CAS  PubMed  Google Scholar 

Matsubayashi K, Kawakami K. Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database. Endocr J. 2020;67:997–1006. https://doi.org/10.1507/ENDOCRJ.EJ20-0129.

Article  PubMed  Google Scholar 

Mestrón A, Webb SM, Astorga R, Benito P, Catalá M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151:439–46. https://doi.org/10.1530/EJE.0.1510439.

Article  PubMed  Google Scholar 

Bex M, Abs R, T’Sjoen G, Mockel J, Velkeniers B, Muermans K, et al. AcroBel–the Belgian registry on acromegaly: a survey of the “real-life” outcome in 418 acromegalic subjects. Eur J Endocrinol. 2007;157:399–409. https://doi.org/10.1530/EJE-07-0358.

Article  CAS  PubMed  Google Scholar 

Schöfl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol. 2012;168:39–47. https://doi.org/10.1530/EJE-12-0602.

Article  CAS  PubMed  Google Scholar 

Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167:189–98. https://doi.org/10.1530/EJE-12-0084.

Article  CAS  PubMed  Google Scholar 

Howlett TA, Willis D, Walker G, Wass JAH, Trainer PJ. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf). 2013;79:689–99. https://doi.org/10.1111/CEN.12207.

Article  CAS  PubMed  Google Scholar 

Mercieca C, Gruppetta M, Vassallo J. Epidemiology, treatment trends and outcomes of acromegaly. Eur J Intern Med. 2012;23. https://doi.org/10.1016/J.EJIM.2012.07.010.

Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16:545–53. https://doi.org/10.1007/S11102-012-0454-0.

Article  PubMed  Google Scholar 

Gatto F, Trifirò G, Lapi F, Cocchiara F, Campana C, Dell’Aquila C, et al. Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrine. 2018;61:533–41. https://doi.org/10.1007/S12020-018-1630-4.

Article  CAS  PubMed  Google Scholar 

Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377–82. https://doi.org/10.1111/J.1365-2265.2009.03667.X.

Article  PubMed  Google Scholar 

Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, García-Dominguez A, Reza-Albarrán AA, et al. The Mexican acromegaly registry: Clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101:3997–4004. https://doi.org/10.1210/JC.2016-1937.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif